Emerging signalling and protein interactions mediated via metabotropic XXXX receptors.

@entity3007 @entity268 @entity2227 @entity859 @entity935 @entity16 @entity302 @entity195 @entity141 @entity385
Metabotropic @entity2227 receptors (mGlu) are @entity3007 -binding (G) protein-coupled receptors (GPCRs) that are involved in learning and memory, cardiovascular control and motor function. Their structure and pharmacology has been reviewed recently in Current Drug Targets: CNS and @entity16 (Vol. 1, Issue 3) where their roles in a variety of @entity16 were highlighted. The present review focuses on the emerging evidence for interactions of mGlu receptors with other GPCRs in the CNS at the membrane interface and amongst signaling cascades in the cytosol (e.g. intracellular @entity141 , @entity268 and scaffolding proteins). While initially non-selective activity was thought to be responsible for many atypical responses, increasing evidence points to GPCR interactions in neurons and glia, with adrenoceptors, @entity859 receptors, @entity935 receptors and muscarinic receptors. For example, group II mGlu receptors were found to be required for group I mGlu receptor induction of long-term potentiation at the postsynaptic terminal. Increasing evidence demonstrates the intimate interaction of @entity859 receptors and mGlu receptors, particularly in the regulation of neurotransmitter release. While @entity859 itself can be released from astrocytes by co-activation of group II mGlu and beta-adrenergic receptors. Given the complexity of @entity16 such as @entity385 , @entity195 and @entity302 , exploitation mGlu receptor-associated GPCR interactions may prove efficacious in the treatment of such disorders.
